Results 71 to 80 of about 66,330 (250)
Biomolecules, 2023 The “block and lock” strategy is one approach that might elicit a sterilizing cure for HIV-1 infection. The “block” refers to a compound’s ability to inhibit latent HIV-1 proviral transcription, while the “lock” refers to its capacity to induce permanent
Benni Vargas +3 more
doaj +1 more source
Advanced Science, EarlyView.RNA structural profiling of Turnip Yellow Mosaic Virus by DMS‐MaPseq and DREEM analyses uncover that viral genome‐wide RSS is highly complicated and heterogeneous, with alternative RSSs widely distributed across the genome. Notably, the viral 3’ tRNA‐like structure adopts alternative conformations in vivo.
Jiaying Zhu +7 more
wiley +1 more source
Interferon-Alpha Mediates Restriction of Human Immunodeficiency Virus Type-1 Replication in Primary Human Macrophages at an Early Stage of Replication [PDF]
, 2010 Type I interferons (IFNα and β) are induced directly in response to viral infection, resulting in an antiviral state for the cell. In vitro studies have shown that IFNα is a potent inhibitor of viral replication; however, its role in HIV-1 infection is ...
McKnight, A +5 more
core +1 more source
Advanced Science, EarlyView.Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv +14 more
wiley +1 more source
Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency [PDF]
, 2011 HIV-1 infection persists even after years of antiretroviral therapy (ART). Although ART can halt viral replication and thereby reduce viremia to clinically undetectable levels, proviral latency established within the host genome remains largely ...
Margolis, David M. +3 more
core +2 more sources
Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
British Journal of Clinical Pharmacology, EarlyView.Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba +2 more
wiley +1 more source
Biotechnology and Bioengineering, EarlyView.Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – Cas9‐based genome editing has emerged as a widely used tool across various disciplines, ranging from molecular biology to gene therapy. This revolutionary technology, which enables precise gene editing, represents a significant advancement in biotechnology, opening new frontiers for ...
Ali Mertcan Köse +3 more
wiley +1 more source
HIV-1 Proviral Transcription and Latency in the New Era [PDF]
Viruses, 2020 Three decades of extensive work in the HIV field have revealed key viral and host cell factors controlling proviral transcription. Various models of transcriptional regulation have emerged based on the collective information from in vitro assays and work in both immortalized and primary cell-based models.
Ashutosh Shukla +2 more
openaire +3 more sources
Control of herpes simplex virus type 1 latency in human trigeminal ganglia [PDF]
, 2012 Herpes simplex virus type 1 (HSV-1) is a double-stranded DNA virus that infects humans and, after a primary lytic infection, establishes lifelong latency in the sensory neurons of the trigeminal ganglia (TG).
Held, Kathrin, Held, K.
core
Gene silencing in HIV-1 latency by polycomb repressive group [PDF]
, 2011 Background The persistence of latently Human immunodeficiency virus-1 (HIV-1) infected cellular reservoirs in resting CD4+ T cells is a major obstacle to HIV-1 eradication. The detailed mechanism of HIV-1 latency remains unclear. We investigated histones
Choi, SY +28 more
core +1 more source